Seedlabs

Membrane-Hsp70 NK-Visibility Tumor Test

A biopsy test that checks if a tumor has the markers needed for NK-cell therapy to work.

A lab test on a tumor biopsy that measures how much Hsp70 sits on the outer surface of cancer cells — a marker the new review shows tumors display but healthy tissues do not, and that serves as a recognition target for natural killer cells — giving NK-cell therapy trials a patient-selection score.

Biochemistry, Genetics and Molecular BiologyHeat shock proteins research
Metabolism and Genetic DisordersImmuno-oncology companion diagnostics — patient selection for NK-cell therapy trials

Concept

A central-laboratory test that quantifies Hsp70 on the outer surface of a patient's tumor cells. The new review reports an unusual membrane localization of Hsp70 on tumor cells but not on corresponding normal tissues, and that this surface Hsp70 acts as a tumor-specific recognition structure for NK cells. The test stains biopsy material (fresh tissue, circulating tumor cells, or archived blocks) with antibodies to surface Hsp70 and reports two numbers: the percentage of membrane-Hsp70-positive tumor cells and the staining intensity. Together these form an NK-visibility score — a pre-treatment, tumor-side indicator of whether the cancer presents the structure NK cells recognize and respond to. Trial teams use the score to enrich enrollment in NK-cell therapy studies and to interpret responder variability; hyperthermia and interventional-oncology programs can use it to select patients for combinations designed to engage NK cells. Delivery is a central-laboratory report for clinical trials, not a consumer product.

Why now

Paper [0] supplies the core evidence: membrane Hsp70 is tumor-selective (found on tumor cells but not corresponding normal tissues), functions as a tumor-specific recognition structure for NK cells, and both soluble and membrane-bound Hsp70 directly activate the cytolytic and migratory capacity of NK cells. The same paper notes that interferon-gamma and fever-range body temperature elevate HSP levels in humans, giving combination trials a timing rationale. Allogeneic NK therapies are multiplying in the clinic, yet patient selection lacks a tumor-side biomarker for NK engagement; a surface-marker test built on a demonstrated tumor-versus-normal difference runs on existing antibody-staining platforms and is immediately buildable for trial use.

Written by GLM · 10 Oct 2026

AI assessment

Backed by 1 paper92

A highly focused companion diagnostic that leverages a specific tumor-surface marker to solve the patient-selection problem for the growing NK-cell therapy market.

Evidence strength
4/5
The research explicitly identifies membrane-bound Hsp70 as tumor-selective and a direct activator of NK cell cytolytic capacity, providing a strong biological basis for the test.
Market pull
5/5
NK-cell therapy developers (e.g., Nkarta, Fate) have a high urgency for biomarkers to reduce trial failure rates and identify responders.
Novelty & moat
4/5
While other Hsp70 ideas exist in the catalog, this is the first to focus specifically on membrane localization as a spatial biomarker for NK-cell visibility.
Feasibility
5/5
The test uses standard antibody-staining (IHC/IF) on biopsy material, which is a mature technology requiring no new hardware development.
Wedge clarity
5/5
The wedge is extremely sharp: a single-marker selection score for clinical trial enrollment in NK-cell therapy.
Simplicity / focus
5/5
The idea avoids 'platform' creep, focusing solely on one protein's localization for one specific clinical outcome.

Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Nkarta Therapeuticscompany

    Developer of allogeneic NK cell therapies; a membrane-Hsp70 score would give its trials a tumor-side biomarker for NK engagement, addressing the field's lack of patient-selection criteria.

  • Fate Therapeuticscompany

    Runs off-the-shelf NK programs where response variability is a key risk; the test would let it enrich enrollment for patients whose tumors display the NK recognition structure.

  • ImmunityBiocompany

    Has NK-cell-based cancer programs; a pre-treatment NK-visibility score would help stratify which patients' tumors are directly targetable by NK mechanisms.

  • The University of Texas MD Anderson Cancer Centerorganization

    Runs NK-cell and hyperthermia clinical trials with in-house correlative laboratories; could adopt the test as a standardized stratification assay across its NK studies.

  • Pyrexar Medicalcompany

    Makes deep-tissue hyperthermia systems; the test identifies patients whose tumors already display the NK-recognition structure, supporting heat-plus-NK combination protocols.

Research it builds on

  1. Immunostimulatory functions of membrane-bound and exported heat shock protein 70
    Jürgen Radons, Gabriele Multhoff · 2026 · 134 citations
    All ideas from this paper →
Leave feedback
feasibility